SEC focusing on drug makers
305997
The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don&#39;t mislead investors
379737
Federal advisers who met last week to consider whether to restrict doses of popular antianemia drugs were themselves under scrutiny during the hearing. The Food and Drug Administration is considering a top-to-bottom reshaping of how it picks and uses the outside scientists who serve on the agency's advisory panels.
640990
Now might be a great time to load up on cutting-edge drug makers.
639887
Learn a lesson or two from the drugmaker's dance with the FDA.
377721
Faced with the threat of generic competition, the company focuses its efforts on a new drug.
240121
Drugmakers get part of the job done outside of the U.S.
286537
A battle between insurers and drug companies could determine how many medicines will be available to beneficiaries.
2234
Makers of the arthritis drug Vioxx and the FDA are the subject of Senate scrutiny today...and an Iowa Senator is asking the tough questions.
440113
Pharmacopeia presents at an investors' conference.
255832
Drug makers are worried that calls for greater disclosure of early-stage clinical trials might lead to the release of scientific information that could help competitors, an industry lobbyist said on Monday.
55690
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's  and Schering-Plough Corp's  popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.
727152
New developments are brewing at the pharmaceutical.
66555
WASHINGTON - The bill Congress is soon expected to pass giving regulators more authority over pharmaceutical companies is most significant to biotech drug makers and their would-be generic rivals because of what was left out.
264090
NEW YORK - As Wall Street sifts through more than 300 third-quarter earnings reports this week, technology and pharmaceutical stocks will be getting some of the closest scrutiny.    The focus on drug companies results from a recent spate of bad news about Merck & Co...
214732
Investors will digest reports from Pfizer and Capital One, among others.
520589
Investors are discouraged after it releases the latest data for its top drug.
519863
The company faces a pivotal clinical trial.